If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the ...

The challenge with curing the Human Immunodeficiency Virus (HIV) is that it tends to hide dormant in cells, evading the ...

HIV is infamous for its ability to hide in the human body for decades, typically requiring long-term treatment to prevent a ...

BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and ...

The antibody, called 04_A06, blocked 98.5% of more than 300 different HIV strains in lab tests, including many resistant to ...

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the ...

Results from pritelivir Phase 2 study demonstrate a favorable safety profile and a numerically higher lesion healing rate vs. foscarnetPritelivir Phase 2 results supported FDA Breakthrough Therapy ...

"We are thrilled to welcome Dr. Gow to our executive team," said Vish Seshadri, Chief Executive Officer of Abeona. "James has ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration ...

A drug that harnesses the immune system to attack cancer cells has proved successful in preventing a rare and aggressive form ...

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation ...

Covid vaccines may come with a tantalizing benefit that has nothing to do with the virus they’re designed to protect against: ...